What changed?

TB-500 Research & Clinical Development Updates

A sourced timeline of research records and material development changes tracked by BACToBasics for TB-500. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.

Tracked items

2

Research sources

1

Development entries

1

Latest recorded date

Verified 2026-09-05

Latest development activity

No established direct human therapeutic development milestone for TB-500 itself.

Verified 2026-09-05 · Preclinical / no established human program · No established development program

For TB-500 itself, credible human therapeutic development has not been established. Human research on full-length thymosin beta-4 should not be counted as TB-500 clinical development.

Open source ↗

Latest research record by publication date

FDA Pharmacy Compounding Advisory Committee — TB-500 Review

Published 2026 · Regulatory · Regulatory evidence review

FDA's review is particularly useful because it separates TB-500 itself from full-length thymosin beta-4 and reports the lack of identified direct human TB-500 clinical evidence.

Open source ↗

Tracked timeline

Research and development record

Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.

Development snapshotVerified 2026-09-05

No established direct human therapeutic development milestone for TB-500 itself.

Preclinical / no established human program · No established development program

For TB-500 itself, credible human therapeutic development has not been established. Human research on full-length thymosin beta-4 should not be counted as TB-500 clinical development.

Research sourcePublished 2026

FDA Pharmacy Compounding Advisory Committee — TB-500 Review

Regulatory · Regulatory evidence review

FDA's review is particularly useful because it separates TB-500 itself from full-length thymosin beta-4 and reports the lack of identified direct human TB-500 clinical evidence.

Follow future TB-500 changes

Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.

Browse all compound updates →Research Library →Clinical Development →

BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.